{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:21:01Z","timestamp":1790655661368,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU21-03-00076"],"award-info":[{"award-number":["NU21-03-00076"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010653","name":"Masarykova Univerzita","doi-asserted-by":"publisher","award":["MUNI\/A\/1587\/2023"],"award-info":[{"award-number":["MUNI\/A\/1587\/2023"]}],"id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"Next generation EU","doi-asserted-by":"crossref","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministerstvo skolstvi, mladeze a telovychovy","award":["CZ.02.01.01\/00\/22_008\/0004644"],"award-info":[{"award-number":["CZ.02.01.01\/00\/22_008\/0004644"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-69408-1","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T12:02:47Z","timestamp":1723550567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients"],"prefix":"10.1038","volume":"14","author":[{"given":"Monika","family":"Vlachov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Pe\u010dinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Gregorov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Mor\u00e1\u0148","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"R\u016f\u017ei\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kova\u010dovicov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Alm\u00e1\u0161i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lud\u011bk","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"\u0160tork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Jel\u00ednek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Popkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ve\u010de\u0159a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Havel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Va\u0148hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"\u0160ev\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"69408_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V. Multiple myeloma: 2022 update on diagnosis, risk-stratification and management. Am. J. Hematol. 97, 1086\u20131107 (2022).","journal-title":"Am. J. Hematol."},{"key":"69408_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538-548 (2014).","journal-title":"Lancet Oncol."},{"key":"69408_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blade","year":"2022","unstructured":"Blade, J. et al. Extramedullary disease in multiple myeloma: A systematic literature review. Blood Cancer J. 12, 1\u201310 (2022).","journal-title":"Blood Cancer J."},{"key":"69408_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosinol","year":"2021","unstructured":"Rosinol, L. et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: Definition, disease assessment and treatment considerations. Br. J. Haematol. 194, 496\u2013507 (2021).","journal-title":"Br. J. Haematol."},{"key":"69408_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","volume":"36","author":"S Sevcikova","year":"2019","unstructured":"Sevcikova, S. et al. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 36, 32\u201339 (2019).","journal-title":"Blood Rev."},{"key":"69408_CR6","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo, M. et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group. Lancet Oncol. 18, e206\u2013e217 (2017).","journal-title":"Lancet Oncol."},{"key":"69408_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ejh.12688","volume":"97","author":"L Besse","year":"2016","unstructured":"Besse, L. et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur. J. Haematol. 97, 93\u2013100 (2016).","journal-title":"Eur. J. Haematol."},{"key":"69408_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour, L. et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99, 360\u2013364 (2014).","journal-title":"Haematologica"},{"key":"69408_CR9","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.3390\/biomedicines10102535","volume":"10","author":"M Stork","year":"2022","unstructured":"Stork, M. et al. Unexpected heterogeneity of newly diagnosed multiple myeloma patients with plasmacytomas. Biomedicines 10, 2535 (2022).","journal-title":"Biomedicines"},{"key":"69408_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjh.17925","volume":"196","author":"M Stork","year":"2022","unstructured":"Stork, M. et al. Identification of patients at high risk of secondary extramedullary multiple myeloma development. Br. J. Haematol. 196, 954\u2013962 (2022).","journal-title":"Br. J. Haematol."},{"key":"69408_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek, T. et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J. Clin. Oncol. 41, 1383\u20131392 (2023).","journal-title":"J. Clin. Oncol."},{"key":"69408_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier, S. et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat. Commun. 9, 1691 (2018).","journal-title":"Nat. Commun."},{"key":"69408_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ejh.13358","volume":"104","author":"D Vrabel","year":"2020","unstructured":"Vrabel, D. et al. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. Eur. J. Haematol. 104, 190\u2013197 (2020).","journal-title":"Eur. J. Haematol."},{"key":"69408_CR14","doi-asserted-by":"publisher","first-page":"e0137294","DOI":"10.1371\/journal.pone.0137294","volume":"10","author":"L Besse","year":"2015","unstructured":"Besse, L. et al. Circulating serum MicroRNA-130a as a novel putative marker of extramedullary myeloma. PLoS One 10, e0137294 (2015).","journal-title":"PLoS One"},{"key":"69408_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3324\/haematol.2013.093500","volume":"99","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova, L. et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 99, 511\u2013518 (2014).","journal-title":"Haematologica"},{"key":"69408_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ejh.12908","volume":"99","author":"L Sedlarikova","year":"2017","unstructured":"Sedlarikova, L. et al. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. Eur. J. Haematol. 99, 223\u2013233 (2017).","journal-title":"Eur. J. Haematol."},{"key":"69408_CR17","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1038\/s41598-019-44215-1","volume":"9","author":"M Deulofeu","year":"2019","unstructured":"Deulofeu, M. et al. Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma. Sci. Rep. 9, 7975 (2019).","journal-title":"Sci. Rep."},{"key":"69408_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ar.20871","volume":"292","author":"Q-T Wang","year":"2009","unstructured":"Wang, Q.-T. et al. Construction of A multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software. Anatom. Record 292, 604\u2013610 (2009).","journal-title":"Anatom. Record"},{"key":"69408_CR19","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","volume":"129","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood 129, 2429\u20132436 (2017).","journal-title":"Blood"},{"key":"69408_CR20","doi-asserted-by":"publisher","first-page":"e0201793","DOI":"10.1371\/journal.pone.0201793","volume":"13","author":"F Barcelo","year":"2018","unstructured":"Barcelo, F. et al. MALDI-TOF analysis of blood serum proteome can predict the presence of monoclonal gammopathy of undetermined significance. PLoS One 13, e0201793 (2018).","journal-title":"PLoS One"},{"key":"69408_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCA.2012.10.032","author":"Y-T Cho","year":"2013","unstructured":"Cho, Y.-T. et al. Matrix-assisted laser desorption ionization\/time-of-flight mass spectrometry for clinical diagnosis. Clin. Chim. Acta 415, 266\u2013275 (2013).","journal-title":"Clin. Chim. Acta"},{"key":"69408_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/BCR3676","author":"L Chung","year":"2014","unstructured":"Chung, L. et al. Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res. 16, R63 (2014).","journal-title":"Breast Cancer Res."},{"key":"69408_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cca.2021.01.021","volume":"516","author":"M Eveillard","year":"2021","unstructured":"Eveillard, M. et al. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. Clin. Chim. Acta 516, 136\u2013141 (2021).","journal-title":"Clin. Chim. Acta"},{"key":"69408_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1373\/clinchem.2015.248146","volume":"62","author":"PJ Jannetto","year":"2016","unstructured":"Jannetto, P. J. & Fitzgerald, R. L. Effective use of mass spectrometry in the clinical laboratory. Clin. Chem. 62, 92\u201398 (2016).","journal-title":"Clin. Chem."},{"key":"69408_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clinbiochem.2017.05.001","volume":"51","author":"MAV Willrich","year":"2018","unstructured":"Willrich, M. A. V., Murray, D. L. & Kyle, R. A. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clin. Biochem. 51, 38\u201347 (2018).","journal-title":"Clin. Biochem."},{"key":"69408_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41467-021-27765-9","volume":"13","author":"D Wolrab","year":"2022","unstructured":"Wolrab, D. et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat. Commun. 13, 124 (2022).","journal-title":"Nat. Commun."},{"key":"69408_CR27","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1021\/jasms.3c00166","volume":"34","author":"L Pecinka","year":"2023","unstructured":"Pecinka, L. et al. Improved screening of monoclonal gammopathy patients by MALDI-TOF mass spectrometry. J. Am. Soc. Mass Spectrom. 34, 2646 (2023).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"69408_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i05","volume":"28","author":"M Kuhn","year":"2008","unstructured":"Kuhn, M. Building predictive models in R using the caret package. J. Stat. Softw. 28, 1\u201326 (2008).","journal-title":"J. Stat. Softw."},{"key":"69408_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-021-01339-6","author":"S Mithraprabhu","year":"2021","unstructured":"Mithraprabhu, S., Chen, M., Savvidou, I., Reale, A. & Spencer, A. Liquid biopsy: An evolving paradigm for the biological characterisation of plasma cell disorders. Leukemia 35, 2771\u20132783 (2021).","journal-title":"Leukemia"},{"key":"69408_CR30","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","volume":"9","author":"H El-Khoury","year":"2022","unstructured":"El-Khoury, H. et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A multicentre cohort study. Lancet Haematol. 9, e340\u2013e349 (2022).","journal-title":"Lancet Haematol."},{"key":"69408_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.clinbiochem.2021.08.001","volume":"97","author":"EM Fatica","year":"2021","unstructured":"Fatica, E. M. et al. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. Clin. Biochem. 97, 67\u201373 (2021).","journal-title":"Clin. Biochem."},{"key":"69408_CR32","doi-asserted-by":"publisher","first-page":"1073479","DOI":"10.3389\/fonc.2022.1073479","volume":"12","author":"J Li","year":"2022","unstructured":"Li, J. et al. MALDI-TOF-MS for rapid screening analysis of M-protein in serum. Front. Oncol. 12, 1073479 (2022).","journal-title":"Front. Oncol."},{"key":"69408_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00408-4","volume":"11","author":"DL Murray","year":"2021","unstructured":"Murray, D. L. et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: An international myeloma working group mass spectrometry committee report. Blood Cancer J. 11, 1\u20136 (2021).","journal-title":"Blood Cancer J."},{"key":"69408_CR34","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/bjh.16443","volume":"189","author":"M Eveillard","year":"2020","unstructured":"Eveillard, M. et al. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. Br. J. Haematol. 189, 904\u2013907 (2020).","journal-title":"Br. J. Haematol."},{"key":"69408_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1309\/AJCPA6C6NOGFLYIR","volume":"134","author":"C Liu","year":"2010","unstructured":"Liu, C. et al. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am. J. Clin. Pathol. 134, 235\u2013241 (2010).","journal-title":"Am. J. Clin. Pathol."},{"key":"69408_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.talanta.2019.03.067","volume":"200","author":"S Long","year":"2019","unstructured":"Long, S. et al. Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma. Talanta 200, 288\u2013292 (2019).","journal-title":"Talanta"},{"key":"69408_CR37","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.ANALCHEM.0C03357","author":"R Santockyte","year":"2021","unstructured":"Santockyte, R. et al. High-throughput therapeutic antibody interference-free high-resolution mass spectrometry assay for monitoring M-proteins in multiple myeloma. Anal. Chem. 93, 834\u2013842 (2021).","journal-title":"Anal. Chem."},{"key":"69408_CR38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1059","author":"K Anderson","year":"2021","unstructured":"Anderson, K. C. et al. Minimal residual disease in myeloma: Application for clinical care and new drug registration. Clin. Cancer Res. 27, 5195\u20135212 (2021).","journal-title":"Clin. Cancer Res."},{"key":"69408_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/RCM.7314","author":"D Barnidge","year":"2015","unstructured":"Barnidge, D. R., Krick, T. P., Griffin, T. J. & Murray, D. L. Using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine. Rapid Commun. Mass Spectrom. 29, 2057\u20132060 (2015).","journal-title":"Rapid Commun. Mass Spectrom. RCM"},{"key":"69408_CR40","doi-asserted-by":"publisher","DOI":"10.1021\/PR400985K","author":"D Barnidge","year":"2014","unstructured":"Barnidge, D. R. et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J. Proteom. Res. 13, 1419\u20131427 (2014).","journal-title":"J. Proteom. Res."},{"key":"69408_CR41","doi-asserted-by":"publisher","DOI":"10.1373\/CLINCHEM.2015.242651","author":"HR Bergen","year":"2016","unstructured":"Bergen, H. R. et al. Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin. Chem. 62, 243\u2013251 (2016).","journal-title":"Clin. Chem."},{"key":"69408_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/J.BEHA.2020.101142","author":"JR Chapman","year":"2020","unstructured":"Chapman, J. R. & Thoren, K. L. Tracking of low disease burden in multiple myeloma: Using mass spectrometry assays in peripheral blood. Best Pract. Res. Clin. Haematol. 33, 101142 (2020).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"69408_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/J.MAYOCP.2021.07.024","author":"S Dasari","year":"2022","unstructured":"Dasari, S. et al. Detection of plasma cell disorders by mass spectrometry: A comprehensive review of 19,523 cases. Mayo Clin. Proc. 97, 294\u2013307 (2022).","journal-title":"Mayo Clin. Proc."},{"key":"69408_CR44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","volume":"9","author":"D Murray","year":"2019","unstructured":"Murray, D. et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer J. 9, 102 (2019).","journal-title":"Blood Cancer J."},{"key":"69408_CR45","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s12185-012-1080-3","volume":"95","author":"A He","year":"2012","unstructured":"He, A. et al. Detection of serum tumor markers in multiple myeloma using the CLINPROT system. Int. J. Hematol. 95, 668\u2013674 (2012).","journal-title":"Int. J. Hematol."},{"key":"69408_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12014-019-9238-0","volume":"16","author":"J Bai","year":"2019","unstructured":"Bai, J. et al. Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma. Clin. Proteom. 16, 17 (2019).","journal-title":"Clin. Proteom."},{"key":"69408_CR47","doi-asserted-by":"crossref","unstructured":"Vanhara, P. et al. Intact cell mass spectrometry for embryonic stem cell biotyping. In Mass spectrometry in life sciences and clinical laboratory (ed. Mitulovic, G.) (IntechOpen, 2020).","DOI":"10.5772\/intechopen.95074"},{"key":"69408_CR48","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/bioinformatics\/bts447","volume":"28","author":"S Gibb","year":"2012","unstructured":"Gibb, S. & Strimmer, K. MALDIquant: A versatile R package for the analysis of mass spectrometry data. Bioinformatics 28, 2270\u20132271 (2012).","journal-title":"Bioinformatics"},{"key":"69408_CR49","unstructured":"R Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria). Available at https:\/\/www.R-project.org (2021)."},{"key":"69408_CR50","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1021\/ac00234a011","volume":"53","author":"MUA Bromba","year":"1981","unstructured":"Bromba, M. U. A. & Ziegler, H. Application hints for Savitzky-Golay digital smoothing filters. Anal. Chem. 53, 1583\u20131586 (1981).","journal-title":"Anal. Chem."},{"key":"69408_CR51","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1080\/01621459.1993.10476408","volume":"88","author":"PJ Rousseeuw","year":"1993","unstructured":"Rousseeuw, P. J. & Croux, C. Alternatives to the median absolute deviation. J. Am. Stat. Assoc. 88, 1273\u20131283 (1993).","journal-title":"J. Am. Stat. Assoc."},{"key":"69408_CR52","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/0168-583X(88)90063-8","volume":"34","author":"CG Ryan","year":"1988","unstructured":"Ryan, C. G., Clayton, E., Griffin, W. L., Sie, S. H. & Cousens, D. R. SNIP, a statistics-sensitive background treatment for the quantitative analysis of PIXE spectra in geoscience applications. Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms 34, 396\u2013402 (1988).","journal-title":"Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms"},{"key":"69408_CR53","doi-asserted-by":"crossref","unstructured":"Kuhn, M. & Johnson, K. Data pre-processing. In Applied Predictive Modeling (eds. Kuhn, M. & Johnson, K.) 27\u201359 (Springer, New York, NY, 2013).","DOI":"10.1007\/978-1-4614-6849-3_3"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69408-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T15:04:43Z","timestamp":1731683083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69408-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["69408"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-69408-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"28 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The original version of this Article was published incorrectly under licence CC BY-NC-ND. The licence has been corrected to CC BY.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18777"}}